Clinical presentation and outcomes in women and men with advanced heart failure
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Clinical presentation and outcomes in women and men with advanced heart failure. / Vishram-Nielsen, Julie K.K.; Deis, Tania; Rossing, Kasper; Wolsk, Emil; Alba, Ana Carolina; Gustafsson, Finn.
I: Scandinavian Cardiovascular Journal, Bind 54, Nr. 6, 2020, s. 1-8.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Clinical presentation and outcomes in women and men with advanced heart failure
AU - Vishram-Nielsen, Julie K.K.
AU - Deis, Tania
AU - Rossing, Kasper
AU - Wolsk, Emil
AU - Alba, Ana Carolina
AU - Gustafsson, Finn
PY - 2020
Y1 - 2020
N2 - Objective: To examine clinical characteristics and outcomes in women and men referred for advanced heart failure (HF) therapies such as left ventricular assist device (LVAD) or heart transplantation (HTx). Design: A retrospective study of 429 (23% women) consecutive adult HF patients not on inotropic or mechanical circulatory support with left ventricular ejection fraction ≤45% referred for assessment of advanced HF therapies at a single tertiary institution between 2002 and 2016. Clinical characteristics and outcomes were compared in women and men, and all patients underwent right heart catheterization (RHC). Results: At evaluation, women were younger than men (48 ± 13 vs. 51 ± 12 years, p =.02), and less likely to have ischemic cardiomyopathy. There were no significant differences in NYHA class, contemporary HF therapy use, or physical examination findings, except for lower jugular vein distension and body surface area in women. On RHC, women had lower cardiac filling pressures, but similar pulmonary vascular resistance and cardiac index. Peak oxygen uptake from cardiopulmonary exercise testing was similar in both sexes. At total follow-up time, there were 164 deaths (21% vs. 44%, p <.0001), 46 LVADs (3% vs. 13%, p =.005), 110 HTxs (32% vs. 25%, p =.15), and 82 HTxs without requiring LVAD (29% vs. 16%, p =.03) in women and men. The time from RHC to HTx (±LVAD) was significantly shorter in women compared to men. Female sex was significantly associated with higher survival independent of time-trend, age, and comorbidities. Conclusion: At evaluation, hemodynamics were less deranged in women. A higher proportion of women received HTx, their waitlist time was shorter, and survival greater.
AB - Objective: To examine clinical characteristics and outcomes in women and men referred for advanced heart failure (HF) therapies such as left ventricular assist device (LVAD) or heart transplantation (HTx). Design: A retrospective study of 429 (23% women) consecutive adult HF patients not on inotropic or mechanical circulatory support with left ventricular ejection fraction ≤45% referred for assessment of advanced HF therapies at a single tertiary institution between 2002 and 2016. Clinical characteristics and outcomes were compared in women and men, and all patients underwent right heart catheterization (RHC). Results: At evaluation, women were younger than men (48 ± 13 vs. 51 ± 12 years, p =.02), and less likely to have ischemic cardiomyopathy. There were no significant differences in NYHA class, contemporary HF therapy use, or physical examination findings, except for lower jugular vein distension and body surface area in women. On RHC, women had lower cardiac filling pressures, but similar pulmonary vascular resistance and cardiac index. Peak oxygen uptake from cardiopulmonary exercise testing was similar in both sexes. At total follow-up time, there were 164 deaths (21% vs. 44%, p <.0001), 46 LVADs (3% vs. 13%, p =.005), 110 HTxs (32% vs. 25%, p =.15), and 82 HTxs without requiring LVAD (29% vs. 16%, p =.03) in women and men. The time from RHC to HTx (±LVAD) was significantly shorter in women compared to men. Female sex was significantly associated with higher survival independent of time-trend, age, and comorbidities. Conclusion: At evaluation, hemodynamics were less deranged in women. A higher proportion of women received HTx, their waitlist time was shorter, and survival greater.
KW - Advanced heart failure
KW - patient characteristics
KW - prognosis
KW - sex
U2 - 10.1080/14017431.2020.1792972
DO - 10.1080/14017431.2020.1792972
M3 - Journal article
C2 - 32666856
AN - SCOPUS:85088013043
VL - 54
SP - 1
EP - 8
JO - Scandinavian Cardiovascular Journal
JF - Scandinavian Cardiovascular Journal
SN - 1401-7458
IS - 6
ER -
ID: 258324484